Our findings may potentially have important implications on drug use especially for genetically uncharacterized patients (AML, NOS) currently accounting for ~40% of all AML as well as other well-characterized patients such as NPM1 mutated samples. This evidence concerns the gene NPM1 and acute myeloid leukemia.